Affiliations

Aurora Sinai Medical Center, Aurora St. Luke's Medical Center

Abstract

Background/Significance:

Tumor-induced osteomalacia (TIO) is an ultra-rare paraneoplastic syndrome caused by excessive fibroblast growth factor 23 (FGF23) secretion from phosphaturic mesenchymal tumors, resulting in hypophosphatemia and osteomalacia. Diagnosis is frequently delayed due to nonspecific symptoms and difficulty localizing small tumors.

Description:

A 55-year-old male presented with 16 months of progressive muscle weakness, multiple bilateral metatarsal fractures, and chronic bone pain. Laboratory evaluation revealed profound hypophosphatemia (1.6 mg/dL), markedly elevated FGF23 (455 RU/mL), and evidence of renal phosphate wasting (TRP 35%, TmP/GFR 1.04 mg/dL). Initial FDG-PET/CT was non-localizing. Upon referral, specialized re-interpretation at a tertiary referral center identified faint focal uptake in the right third metacarpal, subsequently confirmed by technetium-99m sestamibi scanning and MRI, which demonstrated a 1.9 × 1.8 × 1.2 cm soft-tissue mass in the palmar tissues. Surgical excision confirmed a phosphaturic mesenchymal tumor with positive FGF23 in situ hybridization. Serum phosphorus normalized postoperatively, confirming cure.

Discussion:

This case highlights the diagnostic challenges of TIO, particularly the difficulty in localizing the tumor and the critical importance of expert imaging interpretation. Complete surgical resection remains the definitive treatment, with rapid biochemical normalization and symptom improvement. The unusual hand location and initially non-localizing imaging underscore the need for systematic diagnostic approaches and multidisciplinary management in this rare but treatable condition.

Presentation Notes

Presented at Scientific Day; May 20, 2026; Milwaukee, WI.

Full Text of Presentation

wf_yes

Document Type

Poster


 

Open Access

Available to all.

Share

COinS
 
May 20th, 12:00 AM

Tumor-Induced Osteomalacia: A Case Report and Literature Review

Background/Significance:

Tumor-induced osteomalacia (TIO) is an ultra-rare paraneoplastic syndrome caused by excessive fibroblast growth factor 23 (FGF23) secretion from phosphaturic mesenchymal tumors, resulting in hypophosphatemia and osteomalacia. Diagnosis is frequently delayed due to nonspecific symptoms and difficulty localizing small tumors.

Description:

A 55-year-old male presented with 16 months of progressive muscle weakness, multiple bilateral metatarsal fractures, and chronic bone pain. Laboratory evaluation revealed profound hypophosphatemia (1.6 mg/dL), markedly elevated FGF23 (455 RU/mL), and evidence of renal phosphate wasting (TRP 35%, TmP/GFR 1.04 mg/dL). Initial FDG-PET/CT was non-localizing. Upon referral, specialized re-interpretation at a tertiary referral center identified faint focal uptake in the right third metacarpal, subsequently confirmed by technetium-99m sestamibi scanning and MRI, which demonstrated a 1.9 × 1.8 × 1.2 cm soft-tissue mass in the palmar tissues. Surgical excision confirmed a phosphaturic mesenchymal tumor with positive FGF23 in situ hybridization. Serum phosphorus normalized postoperatively, confirming cure.

Discussion:

This case highlights the diagnostic challenges of TIO, particularly the difficulty in localizing the tumor and the critical importance of expert imaging interpretation. Complete surgical resection remains the definitive treatment, with rapid biochemical normalization and symptom improvement. The unusual hand location and initially non-localizing imaging underscore the need for systematic diagnostic approaches and multidisciplinary management in this rare but treatable condition.

 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.